$3.79
4.05% today
Nasdaq, Sep 16, 08:16 pm CET
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Editas Medicine, Inc. Stock price

$3.95
-0.04 1.00% 1M
-4.64 54.02% 6M
-6.18 61.01% YTD
-4.52 53.36% 1Y
-59.01 93.73% 3Y
-21.55 84.51% 5Y
-14.25 78.30% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.20 5.33%
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Key metrics

Market capitalization $325.78m
Enterprise Value $85.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.27
P/S ratio (TTM) P/S ratio 4.86
P/B ratio (TTM) P/B ratio 1.40
Revenue growth (TTM) Revenue growth 247.03%
Revenue (TTM) Revenue $67.03m
EBIT (operating result TTM) EBIT $-213.02m
Free Cash Flow (TTM) Free Cash Flow $-171.54m
Cash position $279.11m
EPS (TTM) EPS $-2.36
P/E forward negative
P/S forward 12.78
EV/Sales forward 3.35
Short interest 27.66%
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Editas Medicine, Inc. forecast:

9x Buy
50%
9x Hold
50%

Analyst Opinions

18 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Editas Medicine, Inc.

Assets
Jun '24
286 286
Cash 279 279
Claims 0.24 0.24
Inventories - -
Other current assets Other current assets Current assets 7 7
98 98
Property, plant and equipment 51 51
Financial assets 43 43
Intangible Assets - -
Other fixed assets Other assets Fixed assets 4.27 4.27
Total Assets 385 385
Liabilities
Jun '24
Equity 232 232
153 153
Current liabilities 74 74
Non-current liabilities 78 78
Total Capital 385 385

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Positive
24/7 Wall Street
10 days ago
There has been a noticeable shift in the stock market over the last two months.
Neutral
Seeking Alpha
11 days ago
Editas Medicine, Inc. (NASDAQ:EDIT ) Wells Fargo 2024 Healthcare Conference September 5, 2024 4:30 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Yanan Zhu - Wells Fargo Securities Yanan Zhu Let's get started. Thanks, everyone, for being here.
Neutral
Seeking Alpha
12 days ago
Editas Medicine, Inc. (NASDAQ:EDIT ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Thanks for joining us everybody.
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 265
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today